# A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

> **NCT00578786** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 383 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** ambrisentan

## Key facts

- **NCT ID:** NCT00578786
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 383 (ACTUAL)
- **Last updated:** 2013-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00578786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00578786, "A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00578786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*